Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research

News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971

Regeneron’s Cholesterol Drug Aces Phase III, Teeing Up US FIling

Thu, 08/15/2019 - 7:38am

The trial linked ANGPTL3 antibody evinacumab to a steep decline in LDL cholesterol in patients with homozygous familial hypercholesterolemia, setting...

      Related Stories 

Sun’s Ilumya Ramps Up In Skyrizi’s Shadow

Wed, 08/14/2019 - 4:49pm

Patient numbers and prescriptions in the US for Sun’s psoriasis therapy Ilumya are steadily on the rise, and the Indian...

      Related Stories 

Evotec Had Strong H1, Foresees Dual Track Growth After Entering Biologics Space

Wed, 08/14/2019 - 8:41am

Evotec upped its full-year guidance after a strong second quarter that saw an important strategic expansion into the biologics space...

      Related Stories 

AZ's Brilinta Patents 'Vulnerable' To Challenge In India

Tue, 08/13/2019 - 5:09pm

An Indian court has lifted restraining orders against Micro Labs, Dr Reddy’s and Natco and held that they have made...

      Related Stories 

Deciphera Plans Ripretinib NDA Filing For Q1 2020 On Phase III GIST Data

Tue, 08/13/2019 - 3:09pm

CEO Steve Hoerter sees best-in-class potential for the drug based on both efficacy and safety in the fourth-line gastrointestinal stromal...

      Related Stories 

Taltz Tops Tremfya In Head-To-Head Psoriasis Study On Complete Skin Clearance

Tue, 08/13/2019 - 10:51am

Lilly's IL-17A inhibitor ixekizumab outperformed J&J's IL-23 inhibitor guselkumab on achieving complete skin clearance in moderate-to-severe psoriasis patients at 12...

      Related Stories 

Pharming Adds CDZ173 To Its Rare Disease Pipeline, Foresees Launch by 2022

Tue, 08/13/2019 - 9:23am

The Dutch rare disease group says licensing CDZ173 from Novartis is Pharming’s first step towards building off the commercial success...

      Related Stories 

Jazz Pharma Zeros In On Essential Tremor With Cavion Buy

Tue, 08/13/2019 - 8:04am

Jazz’s $312.5m acquisition will add to the company’s pipeline of products in neurological conditions, but only at the Phase-II stage.  ...

      Related Stories 

UK's AstronauTx Gets Cash For Alzheimer's Programs

Tue, 08/13/2019 - 7:17am

The Dementia Discovery Fund is backing the UCL spin-off's efforts to develop therapies that modulate astrocyte function.

      Related Stories 

Ebola Success For Regeneron’s Triple Antibody Cocktail

Tue, 08/13/2019 - 6:31am

PALM study stopped early after two agents being tested proved better than ZMapp, the current standard of care, in the...

      Related Stories 

Venture Funding Deals: July Sees Seven Rounds Of $100m Or More

Mon, 08/12/2019 - 3:57pm

Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets...

      Related Stories